论文信息 - Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. - 字舞流文

Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia.

Till Acker | Christof von Kalle | Stefan Fröhling | Hanno Glimm | David Capper | Thomas Mandel | Sascha Dietrich | C. von Kalle | S. Fröhling | T. Acker | D. Capper | A. Ho | H. Glimm | A. Jethwa | C. Blume | J. Hüllein | S. Dietrich | T. Zenz | M. Andrulis | M. Hundemer | B. Garvalov | Anthony D Ho | Thorsten Zenz | N. Lehners | Mindaugas Andrulis | Christoph Schulte | J. Meissner | Julia Meissner | Michael Hundemer | Boyan K Garvalov | Jennifer Hüllein | Nicola Lehners | Alexander Jethwa | Carolin Blume | T. Mandel | C. Schulte | Alexander Jethwa

[1] M. O’connell,et al. Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin). , 1987, The New England journal of medicine.

[2] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[3] W. Wilson,et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. , 2001, The New England journal of medicine.

[4] R. Foà,et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. , 2012, Blood.

[5] C. von Kalle,et al. BRAF inhibition in refractory hairy-cell leukemia. , 2012, The New England journal of medicine.

[6] J. Connors,et al. Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. , 2012, Blood.

[7] K. Flaherty,et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. , 2012, The New England journal of medicine.

[8] D. Carson,et al. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. , 1990, The New England journal of medicine.

[9] S. Pileri,et al. BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.

[10] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[11] Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. , 1998 .

[12] J. Koziol,et al. Filgrastim for Cladribine-Induced Neutropenic Fever in Patients With Hairy Cell Leukemia , 1999 .

[13] M. Raffeld,et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. , 2012, Blood.

[14] F. Mandelli,et al. Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15] A. Ho,et al. Plasma levels of soluble CD8 antigen and interleukin-2 receptor antigen in patients with hairy cell leukemia, relationship with splenectomy and with clinical response to therapy. , 1989, Leukemia.

[16] M. Grever. How I treat hairy cell leukemia. , 2010, Blood.

[17] D. Catovsky,et al. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia , 2011, Leukemia & lymphoma.

[18] A. Rohatiner,et al. Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis , 2009, British journal of haematology.

[19] D. Catovsky,et al. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant* , 2012, British journal of haematology.